RxDoctor Payments Data

Syed Raza, MD

Internal Medicine · Medina, NYNPI 1497715296

Payments from drug & device makers

$471in general payments, 2019–2025

Across 33 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$138
  • AstraZeneca$110
  • Novo Nordisk$78
  • Boehringer Ingelheim$48
  • Philips North America LLC$25
  • Verona Pharma, Inc.$21
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$471 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$27,930
Medicare patients
72
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$126,162
JardianceEmpagliflozin90$88,824
FarxigaDapagliflozin Propanediol71$70,052
EliquisApixaban85$69,554
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$61,707
TrulicityDulaglutide27$36,832
MounjaroTirzepatide26$31,130
Combivent RespimatIpratropium/Albuterol Sulfate64$30,284
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$27,813
XareltoRivaroxaban19$22,679
MyrbetriqMirabegron22$20,143
TradjentaLinagliptin19$17,727
VascepaIcosapent Ethyl18$16,763
Breo ElliptaFluticasone/Vilanterol29$14,994
Tresiba Flextouch U-100Insulin Degludec26$13,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat$48$146,687192 claims
Novo NordiskOzempic$78$126,162124 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$110$110,218169 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Shingrix$138$89,304163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Medina

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →